Zydus launches Mirabegron Extended-Release Tablets in the US
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
23 Apr 24
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and…
22 Apr 24
The approval was based on results from Phase 3 ALINA study in which Alecensa lowered the risk of…
19 Apr 24
The regulator has authorised Entyvio as a maintenance drug for individuals with moderately to highly active Crohn's disease…
19 Apr 24
The pharma company is currently recruiting patients in the Phase 2 GenePHIT study to assess the safety and…
19 Apr 24
Collaboration Leverages Variant Bio's Cutting-edge Genomic Discovery Platform And Evotec's Integrated End-to-end R&d Platform And Disease Area Expertise…
18 Apr 24
Clearmind will get exclusive global rights to develop, research, manufacture, and market products derived from psychedelic compounds, which…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
18 Apr 24
In both the late-stage trials, the drug reduced the AHI against the placebo and achieved a mean AHI…
18 Apr 24
The results of the final trial showed that Shingrix is effective against shingles with high vaccine efficacy rate…
18 Apr 24
Under the collaboration, A*STAR will offer its iPSC banks, specialised monoclonal antibody assets, process scaling, and analytics skills…
18 Apr 24
ReadyGo Diagnostics initiates volume manufacturing of its sample collection and preparation device with Porex.